Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | February 27, 2026 | March 02, 2026 |
| IMMUNIC, INC.IMUX · Entity 6306 | Director | July 05, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date February 27, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2036-02-27 | Direct | 20,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 20,000 · Balance 20,000 F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
IMMUNIC, INC.
Report date July 05, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.80 · Expires 2036-07-05 | Direct | 25,370 |
Reported balance
After 2026-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-05 · Grant · Acquired 25,370 · Balance 25,370 F1: The option vests in monthly increments over a period of one year from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in monthly increments over a period of one year from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 6,692 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.91 · Expires 2034-05-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 42,308 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2026 Filed Jul 7, 2026 16:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 25,370 | $0.00 Strike: $14.80 | $0.00 |
DisclosureSEC source: 0001193805-26-000932 · e665635_4-skerjanec.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,370 Underlying: Common Stock · 25,370 shares Expires 2036-07-05 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 20:34 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 25,370 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193805-26-000891 · e665611_4-skerjanec.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,370 Underlying: Common Stock · 25,370 shares Expires 2036-03-27 F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. F2 · derivative.exercise_date: The option is fully vested as of March 27, 2026. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:22 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,308 | Not disclosed Strike: $28.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-082290 · ownership.xml · derivative · entry 3 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,308 shares Expires 2034-05-13 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:22 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,034 | Not disclosed Strike: $33.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-082290 · ownership.xml · derivative · entry 2 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:22 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 6,692 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082290 · ownership.xml · nonDerivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 23:00 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001193125-26-085918 · ownership.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 10,034 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001599901-25-000121 · wk-form4_1749767434.xml · derivative · entry 2 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · derivative.exercise_date: This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 6,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000121 · wk-form4_1749767434.xml · nonDerivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,692 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001193805-25-000842 · e664611_4-skerjanec.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:11 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001193805-24-000961 · e663799_4-skerjanec.xml · derivative · entry 2 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-07-22 F2 · derivative.exercise_date: Additionally, in respect of such appointment, Reporting Person received from Immunic, Inc. a grant of options to purchase up to 50,000 shares of Immunic, Inc.'s common stock, which vest monthly over one year, effective July 22, 2024. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:11 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001193805-24-000961 · e663799_4-skerjanec.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-07-22 F1 · derivative.exercise_date: In relation to Reporting Person's directorship appointment at Immunic, Inc., Reporting Person received an inducement grant of options to purchase up to 100,000 shares of Immunic, Inc.'s common stock, which vest monthly over three years, effective July 22, 2024. Read SEC document |
| May 14, 2024 Filed May 16, 2024 22:21 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 42,308 | $0.00 Strike: $28.91 | $0.00 |
DisclosureSEC source: 0000950170-24-061255 · ownership.xml · derivative · entry 1 Skerjanec Simona · CIK 0002022163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,308 Underlying: Common Stock · 42,308 shares Expires 2034-05-13 F1 · derivative.exercise_date: The option was granted on May 14, 2024 and shall vest in substantially equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.